iX Biopharma Ltd is an innovative late-stage specialty pharmaceutical company with expertise in drug delivery and formulation.
Our Company has developed a patented, fast-dissolving wafer formulation, WaferiX™; a multiple platform technology (matrix for drug carrier) that can deliver a vast number of drugs approved by regulatory bodies. This administration allows faster delivery and reduction in loss of drugs due to hepatic and gastrointestinal metabolism, hence improving the bioavailability of the drugs.
Sublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner, however avoiding potentially toxic spike in plasma concentration usually seen on painful intravenous administration.
The company’s initial product development focus will be on analgesics and men's health; taking advantage of the rapid onset of action delivered by its proprietary sublingual technology.
We undertake and manage our own research and development in Singapore, Australia and Hong Kong. iX has four subsidiaries in Australia and Hong Kong, namely iX Biopharma Pty Ltd, Syrinx Pharmaceuticals Pty Ltd, Chemical Analysis Pty Ltd and Entity Health Limited. Our manufacturing and laboratory testing facilities in Croydon, Victoria, Australia are Therapeutic Goods Administration ("TGA") approved and current Good Manufacturing Practices ("cGMP") compliant.
iX has a dedicated team of 85 highly skilled and trained professionals, including 14 PhD specialists with vast experience in research and development, manufacturing and analysis.